Hepatitis B Screening Prior to Chemotherapy in the Middle East: A Retrospective Cohort Study
Keywords:Hepatitis B Virus, Antineoplastic Agents, Screening Tests
Background: Hepatitis B virus (HBV) reactivation can be asymptomatic or manifest as fatal fulminant hepatitis. Most international guidelines recommend screening patients prior to immunosuppressive therapy.
Aims: To determine HBV screening rates and modalities in patients receiving chemotherapy at the American University of Beirut Medical Center.
Methods: A retrospective cohort review of electronic health records of adult patients who received chemotherapeutic agents, between June 2015 and June 2016. Patients clinical characteristics were documented. Adequate screening was defined as performing all: HBsAg, HBs Abs, and anti HBc Abs(total).
Results: A total of 1547 patients were initially assessed. 45.6% were males with a mean age of 56. 382(30%) had hematologic malignancies, of whom 111 underwent HSCT. Of those included, 303(24%) patients were screened by at least one test for HBV and 42(3.3%) for HBsAg, anti HBc Abs and HBs Abs.
Patients who were appropriately screened were significantly younger(p=0.008) and more likely to have hematologic malignancies (n=35, 83.3%, p<0.0001). Among patients with hematologic malignancies, appropriately screened patients (n=35) were younger (p=0.042) and had a history of HSCT(n=19, 54.3%, p=0.001).
Conclusion: Rates of screening for HBV prior to chemotherapy at our medical center are low, and not always complete or adequate. There is an urgent need to implement a better screening policy.
Stanaway DJ, Flaxman DA, Naghavi M, Fitzmaurice C, Vos T,
Abubakar I et al. The global burden of viral hepatitis from 1990
to 2013: findings from the Global Burden of Disease Study 2013.
The Lancet. 2016; 388(10049): 1081â€“1088.
Ott J, Stevens G, Groeger J, Wiersma S, Global epidemiology of
hepatitis B virus infection: new estimates of age-specific HBsAg
seroprevalence and endemicity. Vaccine 2012; 30:2212-2219.
Global, regional, and national age-sex specific all-cause and
cause-specific mortality for 240 causes of death, 1990-2013:
a systematic analysis for the Global Burden of Disease Study
Crossref DOI link: https://doi.org/10.1016/S0140-
Schweitzer A, Horn J, Mikolajczyk TR, Krause G, Ott JJ.
Estimations of worldwide prevalence of chronic hepatitis B virus
infection: a systematic review of data published between 1965
and 2013. The Lancet 2015; 386:1546-1555.
Nabulsi MM, El Saleeby CM, Araj GF.The current status of
hepatitis B in Lebanon. LMJ 2003; 51: 64-70.
Specialist Panel on Chronic Hepatitis B in the Middle East. A
review of chronic hepatitis B epidemiology and management
issues in selected countries in the Middle East. J Viral Hepat
; 19: 9-22.
Kusumoto S, Tobinai K. Screening for and management of
hepatitis B virus reactivation in patients treated with anti-B-cell
therapy. ASH Education Program Book 2014; 576-583.
Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D.
Reactivation of hepatitis B virus replication in patients
receiving cytotoxic therapy: report of a prospective study.
Gastroenterology 1991; 100:182-188.
Kim SJ,Hsu C, Song YQ, Tay K, Hong XN, Cao J et al. Hepatitis
B virus reactivation in B-cell lymphoma patients treated with
rituximab: analysis from the Asia Lymphoma Study Group. Eur J
Cancer Prev 2013; 49:3486-3496.
Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino
F et al. Systematic review: the effect of preventive lamivudine on
hepatitis B reactivation during chemotherapy. Ann. Intern Med
; 148: 519-528.
Di Bisceglie AM1, Lok AS, Martin P, Terrault N, Perrillo RP,
Hoofnagle JH. Recent US Food and Drug Administration
warnings on hepatitis B reactivation with immune- suppressing
and anticancer drugs: just the tip of the iceberg? Hepatology
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas
MM et al. Update on prevention, diagnosis, and treatment
of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
Hepatology 2018; 67:1560-1599.
El-Sayed MH, Mohamed MM, Maina AM, Oliveri F, Brunetto
MR, Bonino F. Severe liver disease is caused by HBV rather than
HCV in children with hematological malignancies. Hematology J
Reddy RK, Beavers LK, Hammond PS, Lim KL, Falck-Ytter YY.
American Gastroenterological Association Institute guideline on
the prevention and treatment of hepatitis B virus reactivation
during immunosuppressive drug therapy. Gastroenterology
Abubakar I., Tillmann T., Banerjee A. Global, regional, and
national age-sex specific all-cause and cause-specific mortality
for 240 causes of death, 1990-2013: a systematic analysis for
the Global Burden of Disease Study 2013. The Lancet 2015;
Hwang JP., Fisch MJ., Lok AS, et al. Trends in hepatitis B virus
screening at the onset of chemotherapy in a large US cancer
center. BMC cancer 2013; 13: 534.
Neuss MN, Desch CE, McNiff KK, Eisenberg PD, Gesme DH,
Jacobson JO, et al. A process for measuring the quality of cancer
care: The Quality Oncology Practice Initiative. J Clin Oncol 2005;
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al.
Asian-Pacific clinical practice guidelines on the management of
hepatitis B: a 2015 update. Hepatol. Int 2016; 10, 1-98.
Eupropean for the study of Liver. Clinical Practice Guidelines on
the management of hepatitis B virus infection. J Hepatol 2017;
Weinbaum MC, Mast EE, Ward WJ. Recommendations for
identification and public health management of persons with
chronic hepatitis B virus infection. J. Hepatol 2009; 49:S35-S44.
Hwang PJ, A. S. Artz SA, Somerfield RM. Hepatitis B virus
screening for patients with cancer before therapy: American
Society of Clinical Oncology provisional clinical opinion update.
J Oncol Prac 2015; 11: e487-e489.
Vaughn PB, Doherty AG, Gautam S, Moss CA, Cheifetz SA.
Screening for tuberculosis and hepatitis B prior to the initiation
of anti-tumor necrosis therapy. Inflamm Bowel Dis 2011;
Hwang JP, Fisch MJ, Zhang H, et al. Low rates of hepatitis B virus
screening at the onset of chemotherapy. J Oncol Pract 2012;
Paul S, Shuja A, Tam I, Kim EM, Kang S, Kapulsky L, et
al.Gastroenterologists have suboptimal hepatitis B virus
screening rates in patients receiving immunosuppressive
therapy. Dig Dis Sci 2016; 61:2236-2241.
Nusair M, Rayyan Y, Hammoudeh W, et al. Hepatitis B care
pathway in Jordan: current situation, gaps and recommended
actions. J Virus Erad 2020; 6(1):1-6. 26.
Abaalkhail F , Elsiesy H, AlOmair A, Alghamdi MY, Alalwan A,
AlMasri N,et al. SASLT practice guidelines for the management
of hepatitis B virus. Saudi J Gastroenterol 2014; 20: 5-25.
J. Choi Y, Y.-S. Lim SY. Characteristics, Prevention, and
Management of Hepatitis B Virus (HBV) Reactivation in HBVInfected
Patients Who Require Immunosuppressive Therapy. Int
J InfectDis 2017; 216, S778-S784.
Lao TT, Sahota SD,. Law WL, Cheng KY, Leung YT. Age-specific
prevalence of hepatitis B virus infection in young pregnant
women, Hong Kong Special Administrative Region of China.
Bull World Health Organ 2014; B; 92:782-789.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 3.0 License Â©
Copyright policies & self-archiving
|Author's Pre-print:||author can archive pre-print (ie pre-refereeing)|
|Author's Post-print:||author can archive post-print (ie final draft post-refereeing)|
|Publisher's Version/PDF:||author can archive publisher's version/PDF|